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Abstract: Investigating and assigning gene functions of herpesviruses is a process, which 
profits from consistent technical innovation. Cloning of bacterial artificial chromosomes 
encoding herpesvirus genomes permits nearly unlimited possibilities in the construction of 
genetically modified viruses. Targeted or randomized screening approaches allow rapid 
identification of essential viral proteins. Nevertheless, mapping of essential genes reveals 
only limited insight into function. The usage of dominant-negative (DN) proteins has been 
the tool of choice to dissect functions of proteins during the viral life cycle. DN proteins 
also facilitate the analysis of host-virus interactions. Finally, DNs serve as starting-point for 
design of new antiviral strategies. 
Keywords: dominant-negative; essential genes; random mutagenesis; conditional gene 
expression; deletion; intracellular immunization; herpesvirus; conserved gene blocks 
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1. Scope 
In this article, we will highlight the possibilities of dominant-negative (DN) proteins as tools to 
elucidate gene functions, pathways and processes. Potential benefits of DN proteins as antiviral agents 
in intracellular immunization are mentioned. 
2. The Way to Assign Herpesviral Gene Functions  
2.1. Conservation of genes and protein function in herpesviruses 
The family of herpesviruses comprises important human and many veterinary relevant pathogens. 
Classification of herpesviruses and separation from other virus families is predicated on virion 
structure, cell tropism and virus host range [1]. Their common feature is their ability to infect the host 
for life. There are important other reasons why herpesviruses stand out from other virus families 
namely their high complexity and their perfect adjustment to their host. As more and more sequence 
information of herpesviruses accumulate, analysis and comparison of the genomes allow the 
identification of core genes that are shared within different subfamilies, and unique genes that 
resemble adaptation to fulfill host specific prerequisites. The number of protein coding genes, also 
according to their genome size, vary between the subfamilies whereby α- and γ-herpesvirinae have on 
average around 70-80 genes and β-herpesvirinae around 160-230 [2]. There is a core set of 43 highly 
conserved genes, shared by all herpesviruses, and that are mainly involved in the basic and 
fundamental procedures of the viral life cycle as entry into the cell, DNA replication, packaging of the 
genome and maturation of infectious particles [3]. Although herpesviruses are extensively studied 
there are still genes in the list of the core genes with unknown function [4] (Figure 1). The additional 
species and subfamily specific genes cover areas of cellular tropism, host shut-off or anti-apoptotic 
processes, evasion from the immune system and maintenance of latency [5,6,7,8]. It is very likely that 
most of the remaining genes of unknown function will belong to one of these groups. Not all of these 
genes are necessary for viral replication in the host, but shape the outcome of the infection [9]. 
2.2. Strategies to identify herpesviral gene function 
In order to identify a function of an unknown gene biological and biochemical assays of the wild-
type (wt) protein or the deletion or mutation of the gene, as well as the use of DN mutants [10] and the 
study of their respective phenotypes and meanwhile also computational alignment to homologues 
genes of known function can be used [11,12]. 
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Figure 1. Gene maps of HSV-1, HCMV and EBV genomes. The relative orientation of the 
known genes for HSV-1 (a), HCMV (b) and EBV (c) are shown as arrows (modified from 
Fields, Virology [13]). Green arrows assign genes of which the function is known, 
suggested or highly predicted. Red arrows assign genes with unknown gene function [14]. 
Herpesviruses share a core set of 43 highly conserved genes that are organized in 7 
conserved gene blocks. Here the relative orientation of the core gene blocks is depicted as 
dark blue arrows. In the core gene blocks most genes are essential and highly conserved 
among herpesviruses of different subfamilies. The major function of these genes is known 
or still under investigation. Most genes with yet unknown function are non conserved 
genes at the genome termini. (Accession numbers: HSV-1: X14112; HCMV: NC_001347; 
EBV: NC_007605). UL, US: unique regions; TR, TRL, TRS: terminal repeat; IR, IRL, 
IRS: internal repeats. 
HSV-1
12 34567TRL IRS TRSIRL
UL US
CMV
1 2 3 4 5 6 7TRL IRS TRSIRL
12 34 5 6 7
TRTR IR
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2.2.1. Targeted mutagenesis for genetic analysis of essential herpesviral genes 
One of the most fundamental questions to address when studying a viral gene is whether the gene is 
essential for the viral life cycle in tissue culture or tropism for a specific cell type. At the beginning of 
herpesviral studies essential genes have been found by random screen of temperature-sensitive mutants 
[15,16,17]. Genes essential for a function in only a certain cell type in vitro, therefore determining 
tropism, have been identified by genome analysis of strains attenuated after propagation in specific cell 
lines [18]. Therefore, deletion or disruption of the gene of interest is an important step in evaluating its 
biological role. The first targeted mutations in herpesviruses have been achieved by site-directed 
homologous recombination of plasmids with transfected viral DNA in tissue culture [19], a procedure 
that is limited by the low frequency and specificity of recombination. A milestone in modifying 
herpesviruses was the cloning of their entire genome as bacterial artificial chromosomes (BAC), which 
allows the complete construction of a mutant herpesvirus genome in a controlled manner prior to the 
reconstitution of infectious progeny [20,21,22]. A simple, random approach to identify essential genes 
has been the transposon-mediated mutagenesis of herpesviral genomes encoded in BACs, whereby 
transposon insertion sites were mapped by direct sequencing and the viability or non-viability of virus 
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progeny has been determined from the mutated genomes by reconstitution in tissue culture 
[23,21,24,25,26]. While this approach was very successful for the identification of interesting essential 
genes [27,28], complete analysis to identify all essential genes (at least for certain cell types in vitro) 
has to be done gene by gene [9]. Besides the deletion phenotype, expression timing (immediate-early, 
early and late) as well as protein localization give helpful clues to the role of a herpesvirus gene and 
might allow a classification to a certain step of the replication cycle, achieved by classical biochemical 
studies. Isolated cloned herpesviral genes can be used to study the function in non-infected cells, as for 
example done for the protein localization of a library of Herpes simplex virus (HSV), human 
cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) genes shown by the group of Frappier [14]. 
Nevertheless, analysis of protein functions and localization in the context of the infection is 
indispensable, and mutation and tagging of the target gene has to be done in the viral genome. The 
principles of reverse genetics might offer manifold approaches to analyze mutations that abolish 
localization or binding to partners and, therefore, can give further hints to its function in a pathway. 
Introduction of the mutations can be made either in the original position of the gene using traceless 
mutagenesis allowing the most subtle substitutions [29,30] or in a faster way by introducing them at an 
ectopic side e.g. via FRT/Flp mediated recombination, which avoid off-target effects in the 
endogenous locus that might be responsible for the phenotype [31]. 
2.2.2. Identification of gene function via homology screening 
Computational biology provides information about different viruses and hosts and predictions to 
assign functions to genes can be made by sequence alignments, motif searches and structure modeling. 
Meanwhile 49 herpesviruses genomes are completely sequenced and stored in the GeneBank database 
(http://www.ncbi.nlm.nih.gov/genomes). With the recent advances of new sequencing technologies, it 
is obvious that sequence comparison will get even more meaningful over the years. Comparison of 
conserved genes of different herpesviruses can help to identify important regions and motifs, as done 
e.g. for pUL89 of HCMV [32]. Not only homologies to other viral genes, but also to cellular genes can 
be very interesting as genes might have been acquired by horizontal gene transfer, to abuse the host 
machinery for viral purposes [33]. Several programs allow the search for patterns and motifs that can 
give valuable hints in which process a gene is involved or reveal functionally relevant sequences of a 
protein[34], as for example PPXY motifs indicating functions in budding or DNA binding domains in 
DNA replication, cleavage or packaging. Yet to date there are several viral genes where no clear 
homology can be found and bioinformatic analysis will not provide any information about a putative 
biological role. 
3. Dominant-Negative Proteins 
In need of novel strategies to dissect functions of protein complexes and their roles in diverse 
pathways, the use of DN mutants arise to be an important and forward-looking strategy in virology. 
Before going into detail how DN mutants can be and have been used in the field of herpesvirus 
biology, the term ‘dominant-negative’ requires an explanation.  
In 1987 Ira Herskowitz reported in Nature, how cloned genes altered to encode mutant products are 
capable to inhibit the wt gene product in a cell, thus causing the cell to be deficient in the function of 
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the gene product [10]. In diploid eukaryotic organisms, genes are present in two alleles, one from each 
parent. As a consequence, two different versions of the gene product can be present in the cell. 
Mutants of one allele, which also inhibits the other wt allele product to fulfill its function, are called 
‘dominant-negative’, as they rule over the intact protein. Therefore, in herpesviral genomes that 
encode for only one allele, DN genes have to be complemented either in cis, by an additional viral 
expression cassette or in trans, by the host cell. 
3.1. Mechanism of DN proteins 
There are different methods how a DN mutant may work, which are reviewed in detail from Veitia 
[35,36]. Mutations in the catalytic site of an enzyme are one way how a DN mutant can arise; in that 
case the substrate is bound but not converted and so the balance of the reaction is disturbed. Examples 
in cell biology are mutations in ATPases or GTPases [37,38,39], especially Rho GTPases have been 
widely used [40] (Figure 2A). Very often DN proteins work in complexes, where the inhibitory 
potential ranges from the block of a simple dimer, as for example membrane receptors or transcription 
activators, which can transmit a signal only after dimerization [41,42] (Figure 2B), up to multi-subunit 
complexes (Figure 2C), demonstrated nicely by Barren and Artemyev for G-protein alpha subunit 
complexes [43]. DN mutations in transcription factors can poison a whole pathway if they block the 
binding sites for active mutants, therefore, inhibiting all downstream gene expression. As for example 
in the case of DN mutants of the proto-oncogene p53, resulting in the loss of growth inhibition and 
cancer manifestation [44] (Figure 2D). 
The example of a DN mutant that acts in the wt form as a homo-dimer explains why a DN mutation 
can cause a stronger phenotype than a deletion (in case of a diploid eukaryotic organism). By equal 
expression of wt and DN, homo-dimerization of the two proteins will lead to the formation of wt-wt, 
DN-wt, wt-DN and DN-DN complexes. Therefore only 25% of the dimeric complexes will be 
functional, while in a deletion it would be 50%. Overexpression of the DN protein shifts the ratio more 
to non-functional complexes. As (random) insertion into the eukaryotic genome is still easier to 
achieve than targeted deletion of both alleles, it is obvious why the DN approach is superior to deletion 
mutants. The problem of targeted deletion was partially overcome by the RNAi approach [45], where 
complementary siRNA molecules initiate the degradation of the mRNA of both alleles. A drawback of 
this method is still that down regulation is rarely complete and the knock down is dependent on the 
half life of the gene product. 
Furthermore, DN proteins have one big advantage that cannot be substituted by any deletion, 
namely that they can arrest the complexes or pathways at different steps. Often proteins are dynamic 
and have several functions as they bind to many other proteins or have different localizations 
depending on activation status. Mutating one domain to make it a DN protein, can lead to the 
disturbance of only one function while leaving other domains intact. Therefore, not the most prominent 
phenotype due to the loss of the protein, which may in fact reflect the sum of several functions, but 
several arresting steps can be monitored. 
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Figure 2. Mode of action of DN proteins. DN proteins can inhibit the function of the wt 
protein in different ways. A) Mutation (red arrowhead) in the catalytic domain of an 
enzyme may lead to binding of the substrate (yellow star) but no conversion. B) Schematic 
view of a phosphorylation reaction that is dependant on substrate binding and homo-
dimerization of the DN membrane protein. Mutation of the substrate binding site may lead 
to a bound substrate, that is not released anymore or the binding of the substrate itself is 
inhibited. Mutation in the active site of one of the homo-dimers will not allow reaction on 
the target molecule. In all cases phosphorylation of the target molecule is impaired. C) The 
function of a multi subunit complex can be influenced by mutation of different subunits of 
the complex. In all cases binding of the DN subunit competes with binding of the wt 
subunit. Here the DN protein does not allow binding of another necessary subunit that is 
needed for the whole multi-complex function. D) DN mutation in a transcription factor 
blocks the binding site for the wt transcription factor and thereby inhibiting the 
downstream gene expression. 
 
 
An example for this postulate is the cellular protein Dynamin (Figure 3) that is involved in clathrin-
coated vesicle endocytosis. It consists of five domains, a N-terminal GTP hydrolysis domain, a middle 
domain, a pleckstrin homology (PH) domain a GTPase effector domain (GED) and a C-terminal 
proline-rich domain (PRD) [46]. A well studied DN mutant is the DynaminK44A, a mutant that cannot 
bind GTP resulting in a block of receptor-mediated endocytosis [47,48]. Mutation of residue K535 in 
the PH domain, also giving rise to a DN phenotype, acts by co-oligomerizing with endogenous wt 
Dynamin and indirectly impairs phosphoinositide binding [49,50]. Deletion of the PRD domain by a 
stop codon in place of the Proline 746 of Dynamin interferes with the recruitment of Dynamin to 
clathrin–coated pits and inhibits in a DN fashion receptor-mediated endocytosis [51]. Together with 
the finding that another mutation in the GTPase domain K142A is defective in its ability to change 
conformation although still hydrolyzing GTP, the hypothesis was postulated that the function of 
Dynamin in endocytosis requires both GTP hydrolysis and a resulting conformational change before or 
concomitant with, vesicle scission [52]. Thus, the use of different DN mutants of the same protein can 
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reveal more information than a deletion could have given, as they represent states that can be 
perceived as snap shots of highly dynamic processes. 
Figure 3. Dynamin – a proteins function explained by DN mutants. A) The Dynamin 
protein consists of five different functional domains. Mutations of Dynamin (marked in 
red), at different positions of the protein, generated DN mutants that inhibit different wt 
functions of Dynamin. The different functions of the domains are summarized below the 
scheme. PH: pleckstrin homology domain; GED: GTPase effector domain; PRD: proline-
rich domain. B) Schematical overview of the function of Dynamin in endocytosis. 
Dynamin is recruited to clathrin-coated pits and via GTP hydrolysis results in 
conformational change before, or concomitant with, vesicle scission. Marked in red are the 
different steps where DN mutants of Dynamin could block and were used to investigate 
Dynamin wt functions. 
 
 
4. Elucidating Herpesvirus Biology with the Help of DN Proteins 
Mutants of cellular proteins such as Dynamin can resolve their functions. Of course DN mutants 
can also be used as tools, by inhibiting known steps in cellular pathways and, thereby, analyzing the 
effects on viral infection. In case of Dynamin, DN mutants of the protein serve to study whether 
viruses use receptor-mediated clathrin dependent endocytosis as entry pathway. Thereby, the necessity 
of Dynamin for entry of HIV-1 could be shown [53], but also the fact that HPV-16 does not need this 
entry pathway [54]. 
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4.1. Identification of pathways with cellular DN proteins 
For herpesviruses entry via receptor-mediated endocytosis or via receptor-mediated fusion has been 
postulated [55]. Evidences for both cases exist and might depend on the cell line used for the study. 
Interestingly, use of DN versions of the focal adhesion kinase (FAK), Src-Kinases and RhoGTPase, 
resulted in decreased uptake of Kaposi’s sarcoma associated herpesvirus. This led to the hypothesis, 
that upon binding of the virus to surface receptors, signaling of integrins to FAK activates Src. This 
Src activation may then recruit Clathrin and Dynamin to the cell surface, allowing the bound virus to 
enter the cell via newly formed vesicles [56,57,58,59]. Although viral entry mechanisms are still a 
matter of debate, usage of defined DN mutants can help to elucidate the complex process of 
subsequent steps that happen at the cell membrane. 
After entry, capsids are transported to nuclear pores and the viral DNA is released into the nucleus, 
where viral DNA replication takes place. Study of the cell cycle arrest induced by herpesvirus and the 
resulting apoptosis has been profiting from the huge set of available DN cyclins. Abusing their original 
function in cells, herpesviruses bind to cellular cyclins to control late gene expression. Advani and 
colleagues could demonstrate that a subset of γ2-proteins are not produced in cell lines expressing DN 
cdc2 [60]. Usage of cyclin D3DN helped to understand the localization and function of ICP0 of HSV 
[61]. These examples are just illustrations of what can be or has been done with the help of cellular DN 
proteins. 
Recently, we could prove the anti-apoptotic feature of M36 of murine cytomegalovirus (MCMV) 
by replacing the viral gene with a DN FAS-associated via death domain (FADDDN). While the deletion 
virus ΔM36-MCMV was severely impaired, inhibition of the apoptosis pathway by FADDDN rescued 
virus replication in vitro and in vivo. This novel approach of inserting cellular DN proteins into the 
virus genome has enabled us to define the biological function of M36 and might represent a strategy to 
evaluate other anti-apoptotic viral genes [62]. 
4.2. Identification of pathways with viral DN proteins 
Viral DN genes are in wider use than cellular DNs [63,64,65,66,67,68,69] to analyze viral 
replication cycles. Instead of giving further examples of what can be done with viral DNs in terms of 
identifying pathways and processes on the cell level, we will address the question what can be done in 
the living organism. 
The protein UL9 of HSV1 is the origin binding protein and, therefore, essential for viral replication 
[70]. After successful inhibition of HSV-1 infection in cell culture by the DN protein UL9-C535C 
(UL9DN) Yao and colleagues created a strongly attenuated recombinant herpesvirus (HSV-UL9DN) that 
can conditionally express the UL9DN [71]. The induced expression of the UL9DN abolishes the 
expression of γ2-proteins almost completely as they are dependent on viral DNA replication. Co-
infection of HSV-UL9DN together with wt HSV-1 or HSV-2 inhibited replication of both viruses [72]. 
Intraocular infection of mice with HSV-UL9DN did not lead to an acute herpetic infection. After 
challenge with the wt strain no keratitis and encephalitis was seen, due to strong neutralizing antibody 
titers and cell mediated immunity induced by the mutant [73]. To further increase the safety and 
immunogenicity of HSV-UL9DN as a vaccine the gene of UL9 was deleted and an additional copy of a 
highly immunogenic glycoprotein (gD) inserted. Herpetic skin disease could be prevented using this 
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new derivate CJ9-gD in the guinea pig model [74]. Although the DN approach in vaccine development 
must be carefully considered, as the addition of inhibitory proteins alone may not fulfill the same 
safety criteria as the deletion of essential genes. Furthermore it provides a new feature to vaccines as 
they can now also inhibit herpesvirus DNA replication of the wt type virus in the rare case of a co-
infection of the same cell at the time point of vaccination. 
5. Design of DN Proteins 
In summary, utilization of viral or cellular DNs depicts a promising strategy to investigate and 
dissect the roles of proteins in the viral life cycle. But how can DNs be isolated? Most viral DN 
mutations were generated at random or found by chance. Many cellular DN mutants have been 
discovered by resolving the genotypes to certain inherited diseases, as for example mutations in the 
genes for Collagen causing Osteogenesis Imperfecta [75] or mutations in ras or p53 found in various 
cancer cells [44]. Often truncations of oligomeric proteins have been found to cause a DN effect 
[76,77], although this is not necessarily the case. The attempt to tag the small capsid protein of β-
herpesviruses with the green fluorescent protein, originally with the purpose to study virus entry with a 
labeled capsid, generated strong DNs (GFP-SCP) [78]. In another study a library of random 
fragmented DNA sequences was used to identify truncated proteins that could inhibit bacteriophage 
lysogenicity; from 80.000 mutants only four DN proteins could be identified and the approach seems 
to be only feasible for this special application [79]. Random multiple point mutations, as generated by 
random mutagenesis PCR [80] do not provide direct evidence, which of the changes in the sequence is 
responsible for the resulting phenotype. Rational protein design could be optimal. An absolute 
prerequisite in that case is comprehensive knowledge and information about structural or functional 
domains. This information is limited to only rare cases. A systematic genome-wide screen for DN 
function has been applied to poliovirus. Mutations have been designed either corresponding to 
previously characterized lethal mutations or mutations that have been predicted by a computer 
algorithm to destabilize the protein structures. DN mutations were identified by co-transfecting wt and 
mutated genomes [81]. While this strategy might be suitable for RNA viruses with small genome size 
and where substantial information is already known, it is obvious that such an approach is unfeasible at 
present for the large genomes of herpesviruses. Therefore, to investigate a protein of choice of yet 
unknown function(s), random mutagenesis is a suitable starting point of investigation.  
For this purpose, two methods are generally applicable, alanine-scanning mutagenesis [82,83,84] 
and linker-scanning transposon mutagenesis [85]. While in the alanine-scanning mutagenesis only 
amino acid substitutions to alanine are possible, the linker-scanning mutagenesis can not only create 
additional amino acid insertions but also C-terminal deletions. The production of mutant libraries with 
both methods is simplified by the availability of commercial products. The limiting and time 
consuming step is the evaluation of the received mutants. 
 Generation of DN herpesviral genes by transposon-based mutagenesis can be divided into three 
steps. In the first round, the cloned gene is mutated by a linker-scanning transposon mutagenesis 
approach, generating a library of mutants of the gene of interest. In the second step, mutants are 
reinserted into the herpesviral genome lacking the gene of interest in order to test for their ability to 
complement the deletion phenotype. This will provide information about essential and important 
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regions of the gene. Then mutants that could not rescue the deletion phenotype are screened for their 
DN potential by inserting them into a wt herpesvirus genome in the third step.  
In the following two sections, we will describe two examples in which our group successfully used 
linker-scanning transposon mutagenesis to identify DN mutants of M50 and M53 of MCMV. 
5.1. Comprehensive genetic analysis of herpesviral gene functions by a random transposon 
mutagenesis approach 
We successfully used a Tn7-transposon-based mutagenesis screen on isolated viral genes (reviewed 
in [86]), which introduces a 5 amino acid insertion or a stop codon and reinserted the mutated genes in 
an ectopic position. This random screening approach proved itself to be generally applicable and subtle 
enough to reduce the risk of protein misfolding. As the screen is genome based, the mutants can be 
studied in the biological context and is in general still suitable for high-throughput analysis. These 
comprehensive screens allowed us to identify important sites for functionality of the protein in terms 
of viability of the viral progeny, localization of the protein in the cell as well as binding sites for 
interaction partners. In case of the nuclear egress protein M50 of MCMV the screen revealed the 
importance of the N-terminal part of the protein, identified the binding site to M53 therein, the crucial 
necessity of the transmembrane domain and the importance of a conserved proline stretch, as well as 
an non-essential regions which could be used to tag the protein [87].  
The next protein that we addressed with this comprehensive mutagenesis was M53, the binding 
partner of M50 both forming together the nuclear egress complex (NEC). Detailed analysis of the 
resulting mutants revealed that the very N-terminal part comprises a nuclear localization signal (NLS) 
that could be replaced by the NLS of SV40, the binding site to M50 could be narrowed down to a 
region of 31 amino acids and that there are two important domains (conserved domain 2 and 4) with 
other functions essential for morphogenesis of MCMV [88]. Further improvements to the transposon-
based mutagenesis allowed us to cover targeted genes with insertions of on average at least every fifth 
amino acid (data not shown). 
5.2. Identification of gene function by DN viral genes gained from screening of transposon libraries 
As DN mutations can arrest dynamic processes at different stages and therefore allow an analysis of 
phenotypes that cannot be resolved with deletion mutants, we were keen to find also DN mutants in the 
comprehensive transposon libraries of M50. In the first screening step we used a total of 104 mutants 
of M50 that were inserted into MCMV-ΔM50 genomes to complement the missing gene. Thereby we 
found 34 mutations that possessed a loss-of-function phenotype, meaning that no viruses could be 
reconstituted from the transfected BAC DNA. To analyze if these mutations could also be DN, the 
individual mutants were inserted at an ectopic position into the wt genome. Furthermore the gene 
expression of DN candidates was controlled via a Doxycyclin-inducible expression cassette, which 
also allowed a quantification of the inhibitory effect [89]. Interestingly, no mutation that destroyed the 
binding site to M53 possessed a DN effect. Whereas two insertion mutants, (M50i40, M50i125) as well 
as the targeted deletion mutant M50ΔVR were able to inhibit M50wt function after induction of gene 
expression and therefore leading to a reduction of virus production [90]. Semi-quantitative expression 
analysis by Western Blotting revealed that the DN effect was dependent on the protein amount. Further 
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immunofluorescence analysis of the NEC complex with the DN mutants showed that there was neither 
mislocalization nor decreased stability of the proteins. Therefore, we concluded that the DN function 
affected the interaction of the NEC with another yet unidentified important protein partner. Based on 
sequence alignment with other homologues of M50 a motif within the deleted region of ΔVR was 
identified and the targeted deletion resulted in an even stronger DN effect. Electron Microscopy 
analysis of this mutant M50ΔP showed the expected phenotype, as packaged capsids accumulated in the 
nucleus. Furthermore, the block of capsid export was accompanied by the accumulation of membrane 
stacks within the nucleus. 
Confirmed by the positive results from the M50 screen, we next applied the DN screen to its 
binding partner M53. To this end we tested 46 mutations, which could not rescue the virus MCMV-
ΔM53 phenotype. Unlike the M50 screen here we could find numerous DN mutants, seven insertion 
mutations and four stop-mutations mainly located in the conserved region 4 (CR4) and two DNs in 
CR3. Furthermore, seven insertion mutations in CR2 were heavily attenuated (Popa et al., manuscript 
in preparation). In general, all mutations in CR4 possessed a stronger inhibitory effect than mutations 
in CR2. All CR4 mutants blocked nuclear egress of viral capsids by interfering with the NEC, by 
mislocalization or destabilization. One stop mutant M53S309 was very effective and could block virus 
egress completely. Surprisingly, this effect was not depended on binding to the NEC (in contrast to 
M50DNs) and rather revealed a new function for the M53 protein in DNA cleavage or packaging, as 
imperfect cleavage of unit length genomes could be observed, which has also been shown for the 
positional homolog BFLF2 in EBV[91]. This leads to an accumulation of immature capsids that did 
not contain viral genomes. Another DN mutant M53i207 did not influence capsid maturation, therefore 
indicating that the block might be happening to a latter stage in morphogenesis. These findings 
suggested new functions for M53.  
This screen once more proves that DN proteins can help to elucidate herpesviral morphogenesis 
steps, beyond the analysis of gene deletion mutants by freezing processes at different stages. 
While linker-scanning transposon mutagenesis to identify DN mutants has been applied to cellular 
genes [92,93,94], the impact of this tool has not yet drawn full attention of the herpesvirus field. While 
several groups already use linker-scanning mutagenesis to identify important regions in the gene of 
interest, they did not screen the libraries for DN mutations [95,96]. But, Lin and Spear nicely showed 
in 2007 that several mutations in gB, derived from linker-scanning mutagenesis, exhibit DN features; 
and effect expression at the cell surface and entry activity [97]. Altogether comprehensive transposon-
based screening for DN proteins can be applied to any essential viral gene to identify DN mutations. 
Analysis of nonessential genes might be also possible depending on the availability of read-out 
systems for the resulting phenotype.  
6. Intracellular Immunization - Using the Antiviral Properties of DN Proteins 
Ignoring their possibilities of biotechnological implementation, DN proteins have a bad repute, as 
they are often accompanied by genetic diseases. But the cell can also benefit from DN proteins. The 
replication cycle of retroviruses needs their integration into the host genome. Therefore, most mammal 
genomes contain inserted retroviral sequences (up to 8% for humans [98]). On the search for natural 
inhibitors of retroviral replication, truncated viral proteins, artifacts from incorrectly inserted genomes 
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where found that provide resistance against a new retroviral infection. In mouse, the friend-virus-
susceptibility-1 gene for example counteracts against leukemia virus infection, inhibiting genome 
integration and formation of the provirus. Detailed analysis of the gene revealed its origin as a gag 
derivative from an endogenous retrovirus [99]. Also, in sheep mutated retroviral elements can be found 
that block retroviral morphogenesis [100,101]. Therefore, evolution favored the maintenance of these 
DN viral factors [102]. 
Baltimore defined the term ‘intracellular immunization’ in 1988 [102], based on the finding of 
Friedmann and colleagues that a truncated transcription activator VP16 of HSV-1 inserted into the 
cellular genome can provide DN resistance against HSV-1 infection [76] (Figure 4). Therefore, 
Baltimore suggested this principle to be generally applicable generating antiviral resistance. There are 
several prerequisites to be fulfilled: First, there is the need of a strong DN effect as a potent inhibitor 
of viral replication. This inhibitory effect should be virus-specific without toxicity due to expression. 
Since Baltimore’s first proposal several groups tried to fulfill this task. Especially in the field of HIV 
mutants of gag, env or rev were generated that have DN effects with the intend to produce HIV 
resistant T cells [103,104]. The targeted virus needs not to be a retrovirus, since a truncated N gene of 
rabies virus for example could inhibit viral replication in cell culture [105].  
Figure 4. Intracellular immunization by expression of DN mutants. Stably transformed 
cells can express DN mutants of viral genes in trans. The DN mutant may inhibit and 
outcompete the wt function of the viral protein. This should inhibit viral replication. The 
target protein must fulfill an essential function during the viral life cycle and so DN can 
attack viral replication, nuclear morphogenesis, capsid assembly and packaging of viral 
DNA or viral exit. 
 
 
Most herpesviruses cause relatively mild syndromes in immune competent hosts. Yet, immune 
deficiency and in particular congenital infection is frequently associated with abortion or severe 
malformation. Herpesviruses also threaten lifestock animals. This ranges from equine herpesviruses 
(EHV) infection in horse, bovine herpesvirus (BoHV) in cow, gallid herpesvirus-2 (MDV) in chicken, 
pseudorabies virus (PRV) in swine also to the relatively new discovered Koi-herpesvirus (Cy-HV) 
which gains importance in aquatic cultures. In the USA three billion dollars per year are estimated to 
be lost due to BoHV-1 induced bovine respiratory disease complex [106]. For only few herpesviruses 
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vaccines are available. Still vaccine breaks have occurred regularly, especially in case of MDV as the 
available vaccines only weaken the symptoms, but infected chickens can still shed virus. This can lead 
to the evolution of more virulent strains, which is considered as a threat [107,108]. Intracellular 
immunization might offer an attractive alternative to vaccination in lifestock.  
Smith and Deluca produced the first mouse carrying a DN transgene with the purpose of 
intracellular immunization against HSV-1. Reduction of virus titer was found in 3 of 4 mouse lines. 
Still mice were suffering from weight loss, which was up to 60% compared to control mice, indicating 
toxicity of the constitutively expressed ICP4 mutant [109]. As ICP4 operates by forming a complex 
with the TATA-binding protein (TBP) and TFIIB to activate or repress transcription, it is possible that 
the DN protein still has some intrinsic potential to interact with cellular proteins and thereby disturbing 
transcription in the transgenic mice. Ono and colleagues could transfer the principle of intracellular 
immunization to PRV by a DN chimerical protein, consisting of a DNA binding domain of IE180 of 
PRV and a tail-truncated VP16 of HSV-1, lacking the transcription activation domain. After successful 
application in vitro [110], inhibition of viral replication was additionally shown in transgenic mice 
[111]. While almost all transgenic mice survived PRV challenge, proving the principle success of the 
intracellular immunization, the mice appeared with severe growth defects as described before in the 
HSV-1 resistant mice by Smith and Deluca.  
Thus, side effects of constitutive DN expression are major drawbacks in the generation of virus-
resistant animals. To overcome this problem an inducible expression system of DN proteins was 
suggested. To this end Ono’s group used a Tetracycline inducible expression system that was able to 
interfere with PRV replication after Doxycyclin induction in vitro [112]. This must be seen as a proof-
of-principle, but general application in lifestock is not feasible at this stage. Therefore, we propose that 
a suitable expression system for intracellular immunization must be under control of the target virus. 
Virus responsive elements that are tightly controlled are difficult to produce, but nevertheless this 
seems to be a forward looking strategy.  
7. Conclusions and Perspectives 
Besides ongoing research in the herpesviral field and intense studies on genes with unknown 
functions, the role of the corresponding proteins are still elusive. One major problem of some proteins 
is that they participate in multiple processes, making studies of their function difficult. Deletion of a 
gene will result in a complex phenotype which is hard to explore. Here, DN mutants might be 
invaluable tools to dissect the function of multifunctional proteins. As described above, DNs can 
poison a whole complex and arrest it at a certain stage, but might allow all other functions of the 
protein. This could help to resolve highly dynamic processes.  
Availability, of an appropriate DN is of course fundamental for this kind of studies. In this 
manuscript, we mentioned several possibilities to create DNs. Furthermore, we showed that a linker-
scanning transposon mutagenesis is an attractive method to generate sets of DN proteins which in the 
case of the proteins M50 and M53 of MCMV helped us to elucidate part of their function. Due to the 
progresses in herpesvirus genetics, manipulation of the herpesvirus genome encoded in BACs and so 
providing DNs in cis is a simple procedure. 
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Trans-complementation of herpesviral DNs, termed intracellular immunization, is a versatile and 
promising experimental strategy which deserves further study. This concept proposes that expression 
of a DN protein could inhibit viral replication to generate viral resistance within a cell or a host. 
Within this manuscript we reviewed the first and important steps of intracellular immunization within 
the herpesviral field. The DNs in these proof-of-principle experiments are still associated with 
negative effects on the host. Therefore, further refinements are needed in order to make the procedure 
be generally applicable for creating herpesviral resistant lifestock. A virus inducible expression 
system, which provides the DN only in infected cells and at the time point of infection, may represent 
the solution. 
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